Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Olive

Showing results (231-240 of 276) with videos related to

Pageof 28
Sort By:
Oncoimmunology|January 4, 2018
BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)Audrey Benyamine, Céline Loncle, Etienne Foucher, et al.
Nature Chemical Biology|July 22, 2008
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activationRémi Lasserre, Xiao-Jun Guo, Fabien Conchonaud, et al.
Blood|December 20, 2008
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcomeBruno Chetaille, François Bertucci, Pascal Finetti, et al.
Blood|July 7, 2012
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subsetChristelle Harly, Yves Guillaume, Steven Nedellec, et al.
The Journal of Infectious Diseases|September 17, 2020
A Granulocytic Signature Identifies COVID-19 and Its SeverityJoana Vitte, Aïssatou Bailo Diallo, Asma Boumaza, et al.
The Journal of Infectious Diseases|April 15, 2021
Reply to Chen and VitettaJoana Vitte, Aïssatou Bailo Diallo, Asma Boumaza, et al.
Frontiers in Immunology|May 22, 2018
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory ActivitiesAude Le Roy, Thomas Prébet, Rémy Castellano, et al.
Journal for Immunotherapy of Cancer|May 19, 2022
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunityPierre-Louis Bernard, Rebecca Delconte, Sonia Pastor, et al.
Cell Reports|July 14, 2021
BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cellsCarla E Cano, Christine Pasero, Aude De Gassart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung CancerPhilippe Rochigneux, Aaron Lisberg, Alejandro Garcia, et al.
Pageof 28

Showing results (231-240 of 276) with videos related to

Sort By:
Pageof 28
Oncoimmunology|January 4, 2018
BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)Audrey Benyamine, Céline Loncle, Etienne Foucher, et al.
Nature Chemical Biology|July 22, 2008
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activationRémi Lasserre, Xiao-Jun Guo, Fabien Conchonaud, et al.
Blood|December 20, 2008
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcomeBruno Chetaille, François Bertucci, Pascal Finetti, et al.
Blood|July 7, 2012
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subsetChristelle Harly, Yves Guillaume, Steven Nedellec, et al.
The Journal of Infectious Diseases|September 17, 2020
A Granulocytic Signature Identifies COVID-19 and Its SeverityJoana Vitte, Aïssatou Bailo Diallo, Asma Boumaza, et al.
The Journal of Infectious Diseases|April 15, 2021
Reply to Chen and VitettaJoana Vitte, Aïssatou Bailo Diallo, Asma Boumaza, et al.
Frontiers in Immunology|May 22, 2018
Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory ActivitiesAude Le Roy, Thomas Prébet, Rémy Castellano, et al.
Journal for Immunotherapy of Cancer|May 19, 2022
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunityPierre-Louis Bernard, Rebecca Delconte, Sonia Pastor, et al.
Cell Reports|July 14, 2021
BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cellsCarla E Cano, Christine Pasero, Aude De Gassart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2022
Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung CancerPhilippe Rochigneux, Aaron Lisberg, Alejandro Garcia, et al.
Pageof 28